Therapeutic Use of Aromatase Inhibitors and PARP Inhibitors for Treatment of Malignancies
Summary
USPTO published patent application US20260097020A1 covering methods for treating gliomas including glioblastoma using aromatase inhibitors such as letrozole, optionally combined with PARP inhibitors (olaparib, pamiparib, veliparib, or niraparib). The application was filed September 30, 2025 under application number 19345169. Inventors include Pankaj B. Desai, Aniruddha S. Karve, Bhavesh B. Gabani, Sidharth N. Gadgil, and Gary A. Gudelsky.
What changed
USPTO published patent application US20260097020A1 for methods of treating malignancies including gliomas with aromatase inhibitors and PARP inhibitors. The claims cover administration of letrozole alone or in combination with olaparib, pamiparib, veliparib, or niraparib. Patent applications create no immediate compliance obligations but establish priority dates for the claimed inventions.
Affected parties include pharmaceutical companies developing cancer therapeutics, researchers studying glioma treatments, and potential licensees. Competitors working in this field should review the application claims to assess freedom-to-operate implications. No regulatory approvals or compliance actions are required based solely on this publication.
What to do next
- Monitor for patent grant or examiner rejections
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
THERAPEUTIC USE OF AROMATASE INHIBITORS AND POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS FOR THE TREATMENT OF MALIGNANCIES
Application US20260097020A1 Kind: A1 Apr 09, 2026
Inventors
Pankaj B. Desai, Aniruddha S. Karve, Bhavesh B. Gabani, Sidharth N. Gadgil, Gary A. Gudelsky
Abstract
Methods for treating gliomas, such as glioblastoma, including administering an aromatase inhibitor, such as letrozole, to a subject suffering from a glioma. The method may further include administering the aromatase inhibitor in combination with a poly-ADP ribose polymerase inhibitor, such as olaparib, pamiparib, veliparib or niraparib.
CPC Classifications
A61K 31/4196 A61K 31/4184 A61K 31/454 A61K 31/495 A61K 31/502 A61K 31/551 A61P 35/00
Filing Date
2025-09-30
Application No.
19345169
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.